Therapy Areas: Allergy
ChromaDex, NIH-NIAID Rocky Mountain Laboratories Launch Study to Assess the Therapeutic Potential of Niagen in COVID-19 Animal Models
7 July 2020 - - US-based nutraceutical company ChromaDex Corp. (NASDAQ: CDXC) has launched a preclinical study in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), ...
Regeneron Starts REGN-COV2 Phase 3 COVID-19 Prevention Trial in Collaboration with National Institute of Allergy and Infectious Diseases
6 July 2020 - - US-based biotechnology company Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has initiated late-stage clinical trials evaluating REGN-COV2, Regeneron's investigational doubl...
European Commission Grants Conditional Marketing Authorization for Gilead's Veklury for the Treatment of COVID-19
6 July 2020 - - The European Commission has granted conditional marketing authorisation for Veklury (remdesivir) as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19, US-based ...
Moderna and Catalent Team for Fill-Finish Manufacturing of Moderna's COVID-19 Vaccine Candidate
25 June 2020 - - US-based biotechnology company Moderna, Inc. (NASDAQ: MRNA) and US-based delivery technologies, development, and manufacturing solutions provider Catalent, Inc. (NYSE: CTLT) have forg...
RLF-100 Granted Fast Track Designation by the FDA for the Treatment of Respiratory Distress in COVID-19
24 June 2020 - - The US Food and Drug Administration awarded Fast Track designation to US-based NeuroRx, Inc for the investigation of RLF-100 (Aviptadil) for the treatment of acute lung injury/acute r...
Relief Therapeutics, NeuroRx Expand Clinical Trial Evaluating RLF-100 in Critically Ill COVID-19 Patients with Respiratory Failure to Houston Methodist Hospital
11 June 2020 - - Switzerland-based drug developer Relief Therapeutics Holding AG (SIX: RLF) and its US partner, NeuroRx, Inc. have added Houston Methodist Hospital as a site in their Phase 2 clinical ...
Related Headlines

Chrysalis BioTherapeutics Receives Funding from the National Institutes of Health for COVID-19 Therapeutic Development

New Data from the Phase 3 HELP Study Open-Label Extension Evaluate the Long-Term Safety and Efficacy of Takhzyro in Reducing Hereditary Angioedema Attacks

Relief Therapeutics, NeuroRx Expand Clinical Trial of RLF-100 to All Patients with Critical COVID-19 and Respiratory Failure

FDA Publicly Shares Antibody Test Performance Data from Kits as Part of Validation Study

Relief Therapeutics and NeuroRx Enroll First Patients with RLF- 100 in Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress

BioDot Accelerates Manufacturing to Meet Global COVID-19 Testing Demand

Montefiore and Albert Einstein College of Medicine begins test of new drug combination of baricitinib and remdesivir for fighting COVID-19

Adjuvance Technologies Receives NIH Funding for COVID-19 Vaccine Research

Moderna Touts Positive Interim Phase 1 Data for its mRNA Vaccine Against Novel Coronavirus

Cipla partners with Gilead to expand the access of Remdesivir to COVID-19

CytoAgents Receives NIH Funding to Accelerate Treatment for Cytokine Storm

Moderna Receives FDA Fast Track Designation for mRNA Vaccine Against Novel Coronavirus

Japanese Ministry of Health Approves Veklury (remdesivir) in Japan for Patients with Severe COVID-19

Milken Institute COVID-19 Tracker Update Identifies More Than 100 Vaccines and Nearly 200 Treatments in Development

Moderna and Lonza Team to Manufacture Moderna's Vaccine Against Novel Coronavirus